{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-354716","form_type":"8-K","ticker":"AMLX","cik":"0001658551","company_name":"Amylyx Pharmaceuticals, Inc.","filed_at":"2026-08-18T11:09:58+00:00","discovered_at":"2026-08-18T11:15:03.935196+00:00","generated_at":"2026-08-18T11:15:18.852112+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Amylyx reports positive Phase 3 LUCIDITY results for avexitide in post-bariatric hypoglycemia","bullets":["LUCIDITY met primary endpoint: 55% reduction in composite Level 2/3 hypoglycemic events vs placebo (p=0.000003).","All secondary endpoints met: reductions in SMBG-measured Level 2, CGM-measured Level 2, and adjudicated Level 3 events.","Trial enrolled 78 adults with PBH post-RYGB; randomized 3:2 to 90 mg avexitide SC daily or placebo.","NDA submission to FDA planned by end of 2026; avexitide has Breakthrough Therapy and Orphan Drug designations.","Avexitide well-tolerated; no serious AEs related to treatment; common AEs: diarrhea, injection site erythema, bruising."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-354716","json":"https://secwatch.observer/filing/0001193125-26-354716.json","markdown":"https://secwatch.observer/filing/0001193125-26-354716.md","text":"https://secwatch.observer/filing/0001193125-26-354716.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526354716/0001193125-26-354716-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1658551/000119312526354716/d180533d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-08-18T11:15:18.852112+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}